Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 20Breast Neoplasms 6Polycystic Ovary Syndrome 4Infertility 4Uterine Anomalies 1Sleep Wake Disorders 1Salpingitis 1Salivary Gland Neoplasms 1Primary Ovarian Insufficiency 1Pregnancy, Ectopic 1Neoplasm Metastasis 1Myofibroma 1Metabolic Syndrome 1Lymphoma 1Leiomyoma 1Infertility, Female 1Hypogonadism 1Hodgkin Disease 1Fatty Liver 1Fatigue 1Endometritis 1Endometriosis 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Invasive Nos 1Adenocarcinoma 1

Interventions

bicalutamide 2enzalutamide 1darolutamide 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Panobinostat 1Goserelin 1Doxorubicin 1Cisplatin 1CP protocol 1AZD3514 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bulbo-Spinal Atrophy, X-Linked × Triptorelin Pamoate × Clear all
NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡